GlobeNewswire Press

  1. Nymox Nears Completion Of New Three Year U.S. Long-Term Follow-Up Study Of BPH Drug 5/19/2010
    Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH).
  2. Hemispherx Biopharma Prepares Application To Initiate Phase II Clinical Trials In China With Ampligen® 5/18/2010
    As part of its expanding international program Hemispherx Biopharma, Inc., (the "Company"), announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
  3. Manhattan Pharmaceuticals Completes Merger Transaction With Ariston Pharmaceuticals 3/15/2010
    New York, (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.
  4. Laxai Pharma, Ltd. (f/k/a NexGen Biofuels, Ltd.) Completes Asset Purchase Of OSR Solutions, Inc. As Platform Acquisition For Clinical Research Services 3/15/2010
    Laxai Pharma, Ltd. (f/k/a NexGen Biofuels, Ltd.) (OTCBB:NXGNF) today announced that it has completed its first acquisition in the clinical research services space by purchasing all of the assets of OSR Solutions, Inc. ("OSR"), a New Jersey based contract research organization ("CRO"), for $3.6 million consisting of the following: $1.5mm in cash, $0.75mm in notes, $0.60mm in assumed liabilities, and 5.6mm common shares of Laxai Pharma, Ltd. -- about 10% of the issued and outstanding common shares at closing. The acquisition was financed by a combination of debt and equity.
  5. OraSure Technologies And Roche Diagnostics Sign Worldwide Commercialization Agreement For Fully Automated Oral Fluid Drugs Of Abuse Assays 1/20/2010
    OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics today announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid drugs of abuse assays with OraSure's Intercept® oral specimen collection device.
  6. Integra Foundation Awards Grant To Support Pediatric Neurosurgery Resident Education 12/3/2009
    The Integra Foundation, the philanthropic arm of Integra LifeSciences Corporation (Nasdaq:IART), announced today that it has awarded a $12,000 grant to the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Joint Section for Pediatric Neurosurgery, in support of the section's annual meeting, which is taking place at the Boston Marriott Copley Place in Boston, Massachusetts, December 1-4, 2009.
  7. Icagen Reports Top-Line Results Of Phase IIa Study Of Senicapoc In Exercise-Induced Asthma 10/28/2009
    Icagen, Inc. today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.
  8. Vical's TransVax™ CMV Vaccine Elicits Long-Term Immune Responses In Phase 2 Trial 10/12/2009
    Vical Incorporated announced today that the company's TransVax cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial. Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, presented the data today at the World Vaccine Congress (Lyon, France - October 5-8).
  9. Vical Licensee Sanofi-Aventis Completes Enrollment In Phase 3 Angiogenesis Trial 9/29/2009
    Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects final data from this trial in late 2010.
  10. Icagen Announces Lifting Of Partial Clinical Hold Of ICA-105665 8/4/2009
    Icagen, Inc. (Nasdaq:ICGN) reported today that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist, for the treatment of epilepsy.